Overview

Granisetron 1 mg Tablets Under Fasting Conditions

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the comparative bioavailability between granisetron hydrochloride 1 mg tablets (Teva Pharmaceuticals USA) and Kytril® 1 mg tablets (Roche, USA), after a single-dose in health subjects under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Granisetron